1. Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
   K. Lewandowski et al, 2018, Int J Lab Hem CrossRef
2. Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients
   L. De Roeck et al, 2018, Hematology CrossRef
3. Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report
   Xue-Bing Shi et al, 2019, WJCC CrossRef
4. Co‐occurrence of BCR–ABL1‐positive chronic myeloid leukaemia and CALR‐mutated essential thrombocythaemia
   Victor E. F. Costa et al, 2019, Br J Haematol CrossRef
5. Concomitant presence of JAK2V617F mutation and BCR‑ABL translocation in two patients: A new entity or a variant of myeloproliferative neoplasms (Case report)
   Filipa Mousinho et al, 2018, Mol Med Report CrossRef
6. Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: Is there a correlation?
   Rim Frikha et al, 2021, J Oncol Pharm Pract CrossRef
7. Co-occurrence of JAK2-V617 F mutation and BCR::ABL1 translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combination
   Magda Zanelli et al, 2024, Front. Oncol. CrossRef
8. A Review of Clonal Relationships in Myeloproliferative Neoplasms with Co-mutations of JAK2, CALR or MPL and BCR::ABL1
   Mohammadamin Noorafrooz et al, 2024, Clinical Lymphoma Myeloma and Leukemia CrossRef